OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)

OPKO Health, Inc. (NASDAQ:OPK) is one of the Best American Penny Stocks to Buy According to AnalystsOn July 8, OPKO Health, Inc. (NASDAQ:OPK) in collaboration with Entera Bio Ltd. (NASDAQ: ENTX) announced the selection of their Oral GLP-2 Analog for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism Congress.

This new therapy is a first in class and combines OPKO Health, Inc.’s (NASDAQ:OPK) long-acting GLP-2 agonist with Entera’s N-Tab technology. The display will be in the Forum Hall Foyer 3, focusing on liver and gastrointestinal tract topics. The therapy treats short bowel syndrome, which is a condition where patients struggle to absorb nutrients due to a damaged or shortened intestine. Currently, the only approved treatment is GATTEX, which requires patients to inject themselves once a day. The oral GLP-2 tablet could change this. It aims to provide the same benefits without painful injections. This format may improve patient compliance and comfort.

OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)

A doctor in scrubs discussing a patient’s test results with a small group of concerned family members.

OPKO Health, Inc. (NASDAQ:OPK) is an international biopharmaceutical company that develops and sells medicines, including human growth hormone and treatments for kidney disease.

While we acknowledge the potential of OPK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OPK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.